Evidence map›Paper›PMID 28078432›Full record

ReviewZeitschrift fur Rheumatologie2017

[Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF].

U Kiltz, R Alten, M Fleck, K Krüger, B Manger, U Müller-Ladner, H Nüsslein, M Reuss-Borst, A Schwarting, H Schulze-Koops and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. [Gout].Zeitschrift fur Rheumatologie · 2022
    Article
  4. [Gout].Der Internist · 2021
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

U KiltzRheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. Uta.kiltz@elisabethgruppe.de.
R AltenRheumatologie, Klinische Immunologie, Osteologie, Physikalische Therapie und Sportmedizin, Schlosspark-Klinik, Berlin, Deutschland.
M FleckKlinik und Poliklinik für Innere Medizin I, Klinik für Rheumatologie/Klinische Immunologie, Asklepios-Klinikum, Uniklinikum Regensburg, Bad Abbach, Deutschland.
K KrügerRheumatologisches Praxiszentrum St. Bonifatius, München, Deutschland.
B MangerMedizinische Klinik 3, Universitätsklinikum Erlangen, Erlangen, Deutschland.
U Müller-LadnerAbteilung für Rheumatologie und Klinische Immunologie, Kerckhoff-Klinik, Bad Nauheim, Deutschland.
H NüssleinRheumatologische Schwerpunktpraxis, Nürnberg, Deutschland.
M Reuss-BorstFacharzt-Praxis für Rheumatologie und Onkologie, Bad Bocklet, Deutschland.
A SchwartingRheumatologisch-immunologische Ambulanz, Universitätsklinik Mainz, Mainz, Deutschland.
H Schulze-KoopsKlinikum der Universität München, München, Deutschland.
A K TauscheMedizinische Klinik III, Abteilung für Rheumatologie, Universitätsklinikum Carl Gustav Carus, Dresden, Deutschland.
J BraunRheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland.
Rheumazentrum Ruhrgebiet · DEJohannes Gutenberg University Mainz · DEKerckhoff Klinik · DEPraxis für Hämatologie und Onkologie · DESchlosspark-Klinik · DESt. Bonifatius Hospital · DEUniversitätsklinikum Erlangen · DEUniversity Hospital Carl Gustav Carus · DEUniversity Hospital Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the increasing prevalence of gout, particularly in old age, the disease is becoming of increasing importance in Germany. Gout is one of the most common forms of recurrent inflammatory arthritis and is induced by the deposition of monosodium urate crystals in synovial fluid and other tissues. The principal goals of therapy in chronic gout are the symptomatic treatment of the acute joint inflammation and the causal treatment of the underlying metabolic cause, the hyperuricemia. Only a consistent and permanent reduction of the serum uric acid level ultimately results in an efficient avoidance of further gout attacks and therefore the prevention of structural damage. Due to an often inadequate treatment of gout, the target of healing the disease is often not achieved. A correct and timely diagnosis and adequate assessment of comorbidities associated with gout are, however, of substantial importance for patient and physician to achieve remission of the disease. In order to create a solid basis for a timely and effective treatment of affected patients, in 2016 the German Society of Rheumatology (DGRh) initiated the development of S2e guidelines on gouty arthritis for specialists. This article summarizes these S2e guidelines on the management of gouty arthritis in the specialist sector.

Indexed as

Practice Guidelines as TopicAntirheumatic AgentsArthritis, GoutyClinical Decision-MakingDiagnosis, DifferentialEvidence-Based MedicineGermanyGout SuppressantsHumansHyperuricemiaOutcome Assessment, Health CareRheumatologyTreatment OutcomeUricosuric AgentsAntirheumatic AgentsGout SuppressantsUricosuric AgentsGuidelinesHyperuricemiaInflammationJointManagement

Identifiers

PMID28078432
OpenAlexW2571582792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.